A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Viking (VKTX) stock, Structure (GPCR) stock and others surge after Pfizer’s obesity drug setback. Read more here.

John Fetterman urged Trump to reverse his decision to pull a Biden-era proposal that would have made GLP-1 medications more ...

The state is thinking about requiring Medicaid patients who want to use GLP-1s for weight loss to meet a certain number on the body-mass index or try diet and exercise programs or less expensive ...